Director
Merck & Co., Inc.
West Point, Pennsylvania, United States
Weifeng has been in the field of immunogenicity for more than 10 years. He is an active member in AAPS neutralization antibody (NAb) work group as well as EBF (European Bioanalysis Forum) NAb team; he is also co-leading the NAb assay drug tolerance subteam at AAPS. After join Merck at the end of 2018, Weifeng is now leading Cell Assay group within PCD Regulated Bioanalytics to develop immunogenicity assays for both biologics, vaccines, and cell therapy.
Disclosure information not submitted.
Tuesday, April 25, 2023
2:30 PM – 2:45 PM ET